

Paul Moayyedi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4127499/publications.pdf>

Version: 2024-02-01

465
papers

42,323
citations

1799

103
h-index

2629

194
g-index

486
all docs

486
docs citations

486
times ranked

29927
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of <i>Helicobacter pylori</i> infection – the Maastricht V/Florence Consensus Report. <i>Gut</i> , 2017, 66, 6-30.	12.1	2,245
2	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	27.0	1,745
3	Current concepts in the management of <i>Helicobacter pylori</i> infection: the Maastricht III Consensus Report. <i>Gut</i> , 2007, 56, 772-781.	12.1	1,706
4	Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial. <i>Gastroenterology</i> , 2015, 149, 102-109.e6.	1.3	1,161
5	British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. <i>Gut</i> , 2014, 63, 7-42.	12.1	1,116
6	International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding. <i>Annals of Internal Medicine</i> , 2010, 152, 101.	3.9	944
7	American Gastroenterological Association Institute Guideline on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 148, 819-822.	1.3	816
8	The Toronto Consensus for the Treatment of <i>Helicobacter pylori</i> Infection in Adults. <i>Gastroenterology</i> , 2016, 151, 51-69.e14.	1.3	671
9	Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1547-1561.	0.4	595
10	The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. <i>Gut</i> , 2010, 59, 325-332.	12.1	588
11	Probiotic <i>Bifidobacterium longum</i> NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2017, 153, 448-459.e8.	1.3	542
12	Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression. <i>American Journal of Gastroenterology</i> , 2007, 102, 2047-2056.	0.4	538
13	Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 644-659.	0.4	523
14	Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 142.	7.4	511
15	American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation. <i>American Journal of Gastroenterology</i> , 2014, 109, S2-S26.	0.4	503
16	Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. <i>Gut</i> , 2009, 58, 367-378.	12.1	486
17	<i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. <i>BMJ</i> , The, 2014, 348, g3174-g3174.	6.0	477
18	Antibiotic Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 661-673.	0.4	469

#	ARTICLE	IF	CITATIONS
19	Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2008, 337, a2313-a2313.	2.3	454
20	Gut Microbiota in Patients With Irritable Bowel Syndrome—A Systematic Review. <i>Gastroenterology</i> , 2019, 157, 97-108.	1.3	436
21	ACG and CAG Clinical Guideline: Management of Dyspepsia. <i>American Journal of Gastroenterology</i> , 2017, 112, 988-1013.	0.4	431
22	Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1044-1060.	3.7	423
23	American Gastroenterological Association Technical Review on the Evaluation of Dyspepsia. <i>Gastroenterology</i> , 2005, 129, 1756-1780.	1.3	368
24	Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process. <i>Gastroenterology</i> , 2012, 143, 336-346.	1.3	365
25	Gastro-oesophageal reflux disease. <i>Lancet, The</i> , 2006, 367, 2086-2100.	13.7	362
26	Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. <i>Gut</i> , 2015, 64, 1049-1057.	12.1	360
27	American Gastroenterological Association Technical Review on the Diagnosis and Management of Asymptomatic Neoplastic Pancreatic Cysts. <i>Gastroenterology</i> , 2015, 148, 824-848.e22.	1.3	340
28	Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1350-1365.	0.4	335
29	Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: A Systematic Review. <i>Gastroenterology</i> , 2020, 158, 930-946.e1.	1.3	330
30	Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1279-1286.	4.4	306
31	Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, 21-39.	0.4	303
32	Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. <i>Gastroenterology</i> , 2019, 157, 682-691.e2.	1.3	299
33	Systematic review and economic evaluation of <i>Helicobacter pylori</i> eradication treatment for non-ulcer dyspepsia. <i>BMJ: British Medical Journal</i> , 2000, 321, 659-664.	2.3	296
34	Asia-Pacific consensus guidelines on gastric cancer prevention. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 351-365.	2.8	291
35	A Systematic Review and Meta-Analysis Evaluating the Efficacy of a Gluten-Free Diet and a Low FODMAPS Diet in Treating Symptoms of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1290-1300.	0.4	269
36	Glucocorticosteroid Therapy in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 590-599.	0.4	266

#	ARTICLE	IF	CITATIONS
37	Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. <i>Gastroenterology</i> , 2015, 149, 340-349.e2.	1.3	262
38	American College of Gastroenterology Monograph on Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2018, 113, 1-18.	0.4	262
39	The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1367-1374.	0.4	258
40	An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2011, 106, S2-S25.	0.4	244
41	Detection of Intestinal Metaplasia in Barrett's Esophagus: An Observational Comparator Study Suggests the Need for a Minimum of Eight Biopsies. <i>American Journal of Gastroenterology</i> , 2007, 102, 1154-1161.	0.4	242
42	Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2009, 104, 1831-1843.	0.4	235
43	Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 601-616.	0.4	231
44	<i>Helicobacter pylori</i> eradication therapy to prevent gastric cancer: systematic review and meta-analysis. <i>Gut</i> , 2020, 69, 2113-2121.	12.1	231
45	Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients. <i>Critical Care Medicine</i> , 2013, 41, 693-705.	0.9	228
46	EUS: a meta-analysis of test performance in suspected choledocholithiasis. <i>Gastrointestinal Endoscopy</i> , 2008, 67, 235-244.	1.0	219
47	Yield of Diagnostic Tests for Celiac Disease in Individuals With Symptoms Suggestive of Irritable Bowel Syndrome. <i>Archives of Internal Medicine</i> , 2009, 169, 651.	3.8	216
48	<i>Helicobacter pylori</i> eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. <i>Gastroenterology</i> , 2001, 121, 1120-1126.	1.3	214
49	Efficacy of Immunosuppressive Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 630-642.	0.4	212
50	The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. <i>Gastroenterology</i> , 2004, 127, 1329-1337.	1.3	211
51	Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis. <i>Gastroenterology</i> , 2010, 138, 1502-1513.	1.3	208
52	Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults â€“ Update 2004. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 15-35.	1.7	204
53	Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. <i>Thorax</i> , 2006, 61, 975-979.	5.6	204
54	<i>Helicobacter pylori</i> Eradication Has the Potential to Prevent Gastric Cancer: A State-of-the-Art Critique. <i>American Journal of Gastroenterology</i> , 2005, 100, 2100-2115.	0.4	202

#	ARTICLE	IF	CITATIONS
55	Limited Value of Alarm Features in the Diagnosis of Upper Gastrointestinal Malignancy: Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2006, 131, 390-401.	1.3	201
56	Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. <i>Lancet, The</i> , 2018, 392, 400-408.	13.7	199
57	Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. <i>Canadian Family Physician</i> , 2017, 63, 354-364.	0.4	199
58	Irritable Bowel Syndrome: A 10-Yr Natural History of Symptoms and Factors That Influence Consultation Behavior. <i>American Journal of Gastroenterology</i> , 2008, 103, 1229-1239.	0.4	194
59	Pharmacological interventions for non-ulcer dyspepsia. , 2006, , CD001960.		189
60	Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. <i>Gut</i> , 2010, 59, 605-611.	12.1	189
61	Empiric Quadruple vs. Triple Therapy for Primary Treatment of Helicobacter pylori Infection: Systematic Review and Meta-Analysis of Efficacy and Tolerability. <i>American Journal of Gastroenterology</i> , 2010, 105, 65-73.	0.4	188
62	Review article: current treatment options and management of functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 36, 3-15.	3.7	186
63	Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 144-158.	3.7	185
64	Risk of Upper Gastrointestinal Bleeding With Selective Serotonin Reuptake Inhibitors With or Without Concurrent NonSteroidal Anti-Inflammatory Use: A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2014, 109, 811-819.	0.4	176
65	Systematic Review and Meta-analysis. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1702-1709.	1.9	174
66	Systematic Review and Meta-analysis of the Prevalence of Irritable Bowel Syndrome in Individuals With Dyspepsia. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 401-409.	4.4	173
67	Efficacy of 5-Aminosalicylates in Crohn's Disease: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 617-629.	0.4	170
68	Can the Clinical History Distinguish Between Organic and Functional Dyspepsia?. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1566.	7.4	167
69	An Update of The Cochrane Systematic Review of Helicobacter Pylori Eradication Therapy in Nonulcer Dyspepsia: Resolving The Discrepancy Between Systematic Reviews. <i>American Journal of Gastroenterology</i> , 2003, 98, 2621-2626.	0.4	166
70	What Is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 830-837.e2.	4.4	166
71	Validation of the Rome III Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care. <i>Gastroenterology</i> , 2013, 145, 1262-1270.e1.	1.3	163
72	Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. <i>Lancet, The</i> , 2000, 355, 1665-1669.	13.7	162

#	ARTICLE	IF	CITATIONS
73	Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. <i>Nature Genetics</i> , 2012, 44, 1131-1136.	21.4	162
74	<i>Helicobacter pylori</i> infection in functional dyspepsia. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 168-174.	17.8	157
75	Increased Intestinal Permeability Is Associated With Later Development of Crohn's Disease. <i>Gastroenterology</i> , 2020, 159, 2092-2100.e5.	1.3	156
76	Eradication Therapy in <i>Helicobacter pylori</i> Positive Peptic Ulcer Disease: Systematic Review and Economic Analysis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1833-1855.	0.4	155
77	The proportion of upper gastrointestinal symptoms in the community associated with <i>Helicobacter pylori</i> , lifestyle factors, and nonsteroidal anti-inflammatory drugs. <i>American Journal of Gastroenterology</i> , 2000, 95, 1448-1455.	0.4	154
78	Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. <i>The Cochrane Library</i> , 2010, , CD005415.	2.8	154
79	Diagnostic and Therapeutic Use of Proton Pump Inhibitors in Non-Cardiac Chest Pain: A Metaanalysis. <i>American Journal of Gastroenterology</i> , 2005, 100, 1226-1232.	0.4	151
80	Ethnicity, Gender, and Socioeconomic Status as Risk Factors for Esophagitis and Barrett's Esophagus. <i>American Journal of Epidemiology</i> , 2005, 162, 454-460.	3.4	143
81	An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2009, 104, S8-S35.	0.4	140
82	Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. <i>Gut</i> , 2017, 66, 411-420.	12.1	137
83	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 1441-1451.	12.1	137
84	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. <i>BMJ</i> , The, 2021, 374, n1554.	6.0	136
85	Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 29, 481-496.	3.7	134
86	Relation of adult lifestyle and socioeconomic factors to the prevalence of <i>Helicobacter pylori</i> infection. <i>International Journal of Epidemiology</i> , 2002, 31, 624-631.	1.9	133
87	Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 1363-1373.	10.7	133
88	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1027-1035.	1.7	133
89	Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group. <i>Digestion</i> , 2009, 80, 74-88.	2.3	131
90	Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2012, 107, 167-176.	0.4	130

#	ARTICLE	IF	CITATIONS
91	Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. <i>Gastroenterology</i> , 2002, 122, 588-590.	1.3	124
92	Diagnostic utility of alarm features for colorectal cancer: systematic review and meta-analysis. <i>Gut</i> , 2008, 57, 1545-1553.	12.1	124
93	<i>Helicobacter pylori</i> "Test and Treat" or Endoscopy for Managing Dyspepsia: An Individual Patient Data Meta-analysis. <i>Gastroenterology</i> , 2005, 128, 1838-1844.	1.3	122
94	Ulcerative colitis. <i>BMJ</i> , The, 2013, 346, f432-f432.	6.0	122
95	Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. <i>Gut</i> , 2020, 69, 74-82.	12.1	122
96	Optimum duration of regimens for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2013, , CD008337.	2.8	120
97	Efficacy of Secretagogues in Patients With Irritable Bowel Syndrome With Constipation: Systematic Review and Network Meta-analysis. <i>Gastroenterology</i> , 2018, 155, 1753-1763.	1.3	119
98	The risks of PPI therapy. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2012, 9, 132-139.	17.8	118
99	Guide wire-assisted cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. <i>Endoscopy</i> , 2013, 45, 605-618.	1.8	118
100	BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. <i>American Journal of Gastroenterology</i> , 2015, 110, 662-682.	0.4	116
101	Eradication of <i>Helicobacter pylori</i> for non-ulcer dyspepsia. , 2006, , CD002096.		115
102	The Leeds Dyspepsia Questionnaire: a valid tool for measuring the presence and severity of dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 1257-1262.	3.7	114
103	Management of Barrett's Esophagus in the UK: Overtreated and Underbiopsied but Improved by the Introduction of a National Randomized Trial. <i>American Journal of Gastroenterology</i> , 2008, 103, 1079-1089.	0.4	113
104	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> -positive people. <i>The Cochrane Library</i> , 2016, 2016, CD003840.	2.8	112
105	Changing Patterns of <i>Helicobacter pylori</i> Gastritis in Long-Standing Acid Suppression. <i>Helicobacter</i> , 2000, 5, 206-214.	3.5	111
106	Faecal microbiota transplantation for <i>Clostridium difficile</i> -associated diarrhoea: a systematic review of randomised controlled trials. <i>Medical Journal of Australia</i> , 2017, 207, 166-172.	1.7	109
107	Anxiety and Depression Increase in a Stepwise Manner in Parallel With Multiple FGIDs and Symptom Severity and Frequency. <i>American Journal of Gastroenterology</i> , 2015, 110, 1038-1048.	0.4	108
108	Pantoprazole to Prevent Gastrointestinal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. <i>Gastroenterology</i> , 2019, 157, 403-412.e5.	1.3	108

#	ARTICLE	IF	CITATIONS
109	Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 117-131.	8.1	108
110	Adverse events with bismuth salts for <i>Helicobacter pylori</i> eradication: Systematic review and meta-analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 7361.	3.3	107
111	Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. <i>BMC Pregnancy and Childbirth</i> , 2018, 18, 14.	2.4	105
112	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 6-29.	0.3	104
113	Inconsistent Definitions for Intention-To-Treat in Relation to Missing Outcome Data: Systematic Review of the Methods Literature. <i>PLoS ONE</i> , 2012, 7, e49163.	2.5	101
114	Medical treatments in the short term management of reflux oesophagitis. , 2007, , CD003244.		100
115	Will the History and Physical Examination Help Establish That Irritable Bowel Syndrome Is Causing This Patient's Lower Gastrointestinal Tract Symptoms?. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1793.	7.4	98
116	Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. <i>Gut</i> , 2007, 56, 321-327.	12.1	96
117	Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis. <i>Gastroenterology</i> , 2021, 160, 1532-1545.	1.3	94
118	Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett's Esophagus. <i>Gastroenterology</i> , 2015, 148, 367-378.	1.3	93
119	Gastric Cancer Consensus Conference Recommends <i>Helicobacter pylori</i> Screening and Treatment in Asymptomatic Persons From High-Risk Populations to Prevent Gastric Cancer. <i>American Journal of Gastroenterology</i> , 2008, 103, 510-514.	0.4	92
120	Deprescribing versus continuation of chronic proton pump inhibitor use in adults. <i>The Cochrane Library</i> , 2017, 2017, CD011969.	2.8	92
121	Bile reflux gastritis and Barrett's oesophagus: further evidence of a role for duodenogastro-oesophageal reflux?. <i>Gut</i> , 2001, 49, 359-363.	12.1	91
122	5-Aminosalicylates Prevent Relapse of Crohn's Disease After Surgically Induced Remission: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 413-420.	0.4	91
123	Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. <i>Gastroenterology</i> , 2017, 153, 395-409.e3.	1.3	90
124	Medical treatments in the short term management of reflux oesophagitis. <i>The Cochrane Library</i> , 2011, , CD003244.	2.8	88
125	Bile reflux gastritis and intestinal metaplasia at the cardia. <i>Gut</i> , 2002, 51, 351-355.	12.1	87
126	The cost-effectiveness of population <i>Helicobacter pylori</i> screening and treatment: a Markov model using economic data from a randomized controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 559-568.	3.7	87

#	ARTICLE	IF	CITATIONS
127	Characteristics of functional bowel disorder patients: a cross-sectional survey using the Rome III criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 312-321.	3.7	87
128	Review article: gastroesophageal reflux disease – the extent of the problem. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 11-19.	3.7	86
129	Eradication therapy for peptic ulcer disease in <i>Helicobacter pylori</i> positive patients. , 2006, , CD003840.		85
130	<i>Helicobacter pylori</i> eradication for the prevention of gastric neoplasia. , 2015, , CD005583.		85
131	Methodology for Randomized Trials of Patients With Nonvariceal Upper Gastrointestinal Bleeding: Recommendations From an International Consensus Conference. <i>American Journal of Gastroenterology</i> , 2010, 105, 540-550.	0.4	83
132	<i>Helicobacter pylori</i> test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). <i>BMJ: British Medical Journal</i> , 2008, 336, 651-654.	2.3	81
133	Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice. <i>United European Gastroenterology Journal</i> , 2017, 5, 773-788.	3.8	81
134	Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1483-1490.	3.7	80
135	Effect of Comorbidity on Mortality in Patients With Peptic Ulcer Bleeding: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2013, 108, 331-345.	0.4	79
136	Proton pump inhibitors for functional dyspepsia. <i>The Cochrane Library</i> , 2018, 2018, CD011194.	2.8	78
137	How Can the Current Strategies for <i>Helicobacter pylori</i> Eradication Therapy be Improved?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2003, 17, 36B-40B.	1.7	77
138	The Usefulness of The Likelihood Ratio in The Diagnosis of Dyspepsia and Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 1999, 94, 3122-3125.	0.4	75
139	Does Fecal Occult Blood Testing Really Reduce Mortality? A Reanalysis of Systematic Review Data. <i>American Journal of Gastroenterology</i> , 2006, 101, 380-384.	0.4	75
140	Prevalence of Uninvestigated Dyspepsia 8 Years After a Large Waterborne Outbreak of Bacterial Dysentery: A Cohort Study. <i>Gastroenterology</i> , 2010, 138, 1727-1736.	1.3	75
141	Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with <i>clostridium difficile</i> . <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1540-1546.	1.9	75
142	Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. , 2004, , CD003245.		74
143	Mortality rates in patients with Barrett's oesophagus. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 316-320.	3.7	74
144	Effect of Dyspepsia on Survival: A Longitudinal 10-Year Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2012, 107, 912-921.	0.4	74

#	ARTICLE	IF	CITATIONS
145	The Short-Form Leeds Dyspepsia Questionnaire validation study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 477-486.	3.7	73
146	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1-13.	1.9	73
147	The Rome III Criteria for the Diagnosis of Functional Dyspepsia in Secondary Care Are Not Superior to Previous Definitions. <i>Gastroenterology</i> , 2014, 146, 932-940.e1.	1.3	71
148	Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease.. <i>Thorax</i> , 1995, 50, 834-837.	5.6	70
149	Symptom-Based Outcome Measures for Dyspepsia and GERD Trials: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2005, 100, 442-452.	0.4	70
150	Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 449-458.	3.7	70
151	Exaggerated systemic antibody response to mucosal <i>Helicobacter pylori</i> infection in IgA nephropathy. <i>American Journal of Kidney Diseases</i> , 1999, 33, 1049-1057.	1.9	69
152	Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 816-823.	1.5	69
153	Prokinetics for Functional Dyspepsia: A Systematic Review and Meta-Analysis of Randomized Control Trials. <i>American Journal of Gastroenterology</i> , 2019, 114, 233-243.	0.4	69
154	Systematic review: antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1215-1227.	3.7	67
155	The methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 631-641.	3.7	65
156	A Community Screening Program for <i>Helicobacter pylori</i> Saves Money: 10-Year Follow-up of a Randomized Controlled Trial. <i>Gastroenterology</i> , 2005, 129, 1910-1917.	1.3	65
157	Who Consults With Dyspepsia? Results from a Longitudinal 10-Yr Follow-Up Study. <i>American Journal of Gastroenterology</i> , 2007, 102, 957-965.	0.4	65
158	Meta-analysis: Can We Mix Apples and Oranges?. <i>American Journal of Gastroenterology</i> , 2004, 99, 2297-2301.	0.4	63
159	Initial management strategies for dyspepsia. , 2005, , CD001961.		63
160	Patient factors that predict failure of omeprazole, clarithromycin, and tinidazole to eradicate <i>Helicobacter pylori</i> . <i>Journal of Gastroenterology</i> , 1997, 32, 24-27.	5.1	61
161	Sequential regimens for <i>Helicobacter pylori</i> eradication. <i>Lancet</i> , The, 2007, 370, 1010-1012.	13.7	58
162	Recommendations on Chronic Constipation (Including Constipation Associated with Irritable Bowel) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.7	57

#	ARTICLE	IF	CITATIONS
163	The Epidemiology of Obesity and Gastrointestinal and Other Diseases: An Overview. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2293-2299.	2.3	57
164	Effect of Comorbidity on Mortality in Patients with Peptic Ulcer Bleeding - A Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2010, 105, S40.	0.4	57
165	Association Between Inflammatory Bowel Diseases and Celiac Disease: A Systematic Review and Meta-Analysis. <i>Gastroenterology</i> , 2020, 159, 884-903.e31.	1.3	54
166	Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 8-21.	3.7	53
167	Eradication of <i>Helicobacter pylori</i> : Omeprazole in Combination with Antibiotics. <i>Scandinavian Journal of Gastroenterology</i> , 1996, 31, 82-89.	1.5	52
168	<i>Helicobacter pylori</i> infection is related to atheroma in patients undergoing coronary angiography. <i>Cardiovascular Research</i> , 1997, 35, 120-124.	3.8	52
169	Meta-analysis: yield of diagnostic tests for coeliac disease in dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 28-36.	3.7	52
170	Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2070-2077.	0.4	52
171	The optimal antibiotic combination in a 5-day <i>Helicobacter pylori</i> eradication regimen. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 497-501.	3.7	51
172	Eradication of <i>Helicobacter pylori</i> for non-ulcer dyspepsia. , 2005, , CD002096.		51
173	Fluctuation of gastrointestinal symptoms in the community: a 10-year longitudinal follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 1013-1020.	3.7	51
174	Do patients need to fast for a 13C-urea breath test?. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 275-277.	1.6	50
175	Meta-analysis: <i>Helicobacter pylori</i> test and treat™ compared with empirical acid suppression for managing dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 534-544.	3.7	49
176	Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. <i>The Cochrane Library</i> , 2010, , CD003245.	2.8	49
177	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Gastroenterology</i> , 2019, 157, 320-348.	1.3	49
178	A Systematic Review of Psychological Therapies for Nonulcer Dyspepsia. <i>American Journal of Gastroenterology</i> , 2004, 99, 1817-1822.	0.4	48
179	The Effect of Dietary Intervention on Irritable Bowel Syndrome: A Systematic Review. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e107.	2.5	48
180	Gluten Introduction to Infant Feeding and Risk of Celiac Disease: Systematic Review and Meta-Analysis. <i>Journal of Pediatrics</i> , 2016, 168, 132-143.e3.	1.8	47

#	ARTICLE	IF	CITATIONS
181	Double-guidewire technique in difficult biliary cannulation for the prevention of post-ERCP pancreatitis: a systematic review and meta-analysis. <i>Endoscopy</i> , 2017, 49, 15-26.	1.8	47
182	Re: Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus. <i>Journal of the National Cancer Institute</i> , 2004, 96, 885-887.	6.3	46
183	Evidence-based and mechanistic insights into exclusion diets for IBS. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 406-413.	17.8	46
184	International Comparisons of Manpower in Gastroenterology. <i>American Journal of Gastroenterology</i> , 2007, 102, 478-481.	0.4	45
185	Errors in the Conduct of Systematic Reviews of Pharmacological Interventions for Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2010, 105, 280-288.	0.4	45
186	Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial. <i>Journal of Medical Screening</i> , 2015, 22, 158-164.	2.3	45
187	Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 513-519.	4.4	44
188	Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. <i>The Cochrane Library</i> , 2012, 12, CD009662.	2.8	43
189	Proton Pump Inhibitors and Risk of Bone Fractures. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 414-423.	0.8	43
190	Psychological interventions for non-ulcer dyspepsia. , 2005, , CD002301.		42
191	Characterization of Simultaneous Pressure Waves as Biomarkers for Colonic Motility Assessed by High-Resolution Colonic Manometry. <i>Frontiers in Physiology</i> , 2018, 9, 1248.	2.8	42
192	Comparison of One or Two Weeks of Lansoprazole, Amoxicillin, and Clarithromycin in the Treatment of <i>Helicobacter pylori</i> . <i>Helicobacter</i> , 1996, 1, 71-74.	3.5	41
193	Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 249-256.	1.6	41
194	Proton pump inhibitors for functional dyspepsia. <i>The Cochrane Library</i> , 2017, 3, CD011194.	2.8	40
195	Probiotics for Celiac Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2020, 115, 1584-1595.	0.4	40
196	<i>Helicobacter pylori</i> eradication for the prevention of gastric neoplasia. <i>The Cochrane Library</i> , 2020, 7, CD005583.	2.8	39
197	Functional Dyspepsia Treatment Trial (FDTT): A double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. <i>Contemporary Clinical Trials</i> , 2012, 33, 523-533.	1.8	38
198	Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma. <i>Gut</i> , 2017, 66, 1739-1747.	12.1	38

#	ARTICLE	IF	CITATIONS
199	The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating <i>Helicobacter pylori</i> in a community screen and treat programme. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 719-728.	3.7	36
200	The Gain in Quality-Adjusted Life Months by Switching to Esomeprazole in Those With Continued Reflux Symptoms in Primary Care: EncompASSâ€”A Cluster-Randomized Trial. <i>American Journal of Gastroenterology</i> , 2010, 105, 2341-2346.	0.4	36
201	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
202	Anxiety But Not Depression Predicts Poor Outcomes in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1255-1261.	1.9	36
203	Canadian Association of Gastroenterology Position Statement: Fecal Microbiota Transplant Therapy. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2014, 28, 66-68.	1.9	35
204	Anti-Microbial Antibody Response is Associated With Future Onset of Crohnâ€™s Disease Independent of Biomarkers of Altered Gut Barrier Function, Subclinical Inflammation, and Genetic Risk. <i>Gastroenterology</i> , 2021, 161, 1540-1551.	1.3	35
205	Results of the First Pilot Randomized Controlled Trial of Fecal Microbiota Transplant In Pediatric Ulcerative Colitis: Lessons, Limitations, and Future Prospects. <i>Gastroenterology</i> , 2021, 161, 388-393.e3.	1.3	35
206	Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. , 2006, , CD005415.		34
207	Who Provides Gastrointestinal Endoscopy in Canada?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2007, 21, 843-846.	1.7	34
208	Current Guidelines for Dyspepsia Management. <i>Digestive Diseases</i> , 2008, 26, 225-230.	1.9	34
209	Prokinetics for functional dyspepsia. <i>The Cochrane Library</i> , 2018, 2018, CD009431.	2.8	34
210	Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate <i>Helicobacter pylori</i> . <i>Journal of Gastroenterology</i> , 1998, 33, 160-163.	5.1	33
211	Tax-Deductible Provisions for Gluten-Free Diet in Canada Compared with Systems for Gluten-Free Diet Coverage Available in Various Countries. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 104-110.	1.9	33
212	FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects. <i>Gut Microbes</i> , 2018, 9, 1-12.	9.8	33
213	The effectiveness of screening and treating <i>Helicobacter pylori</i> in the management of dyspepsia. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 1245-1250.	1.6	32
214	<i>Helicobacter pylori</i> Public Health Implications. <i>Helicobacter</i> , 2004, 9, 67-72.	3.5	32
215	The health economics of <i>Helicobacter pylori</i> infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2007, 21, 347-361.	2.4	32
216	Psychological interventions for non-ulcer dyspepsia. <i>The Cochrane Library</i> , 2011, 2011, CD002301.	2.8	32

#	ARTICLE	IF	CITATIONS
217	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1680-1713.	4.4	32
218	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e1-e34.	0.3	32
219	Effect of sibling number in the household and birth order on prevalence of <i>Helicobacter pylori</i> : a cross-sectional study. <i>International Journal of Epidemiology</i> , 2007, 36, 1327-1333.	1.9	31
220	Efficacy of <i>Helicobacter pylori</i> eradication therapy for functional dyspepsia: updated systematic review and meta-analysis. <i>Gut</i> , 2022, 71, 1967-1975.	12.1	31
221	Gluten-Free Diet Reduces Symptoms, Particularly Diarrhea, in Patients With Irritable Bowel Syndrome and Antigliadin IgG. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2343-2352.e8.	4.4	30
222	<i>Helicobacter pylori</i> Eradication for Functional Dyspepsia: What Are We Treating?. <i>Archives of Internal Medicine</i> , 2011, 171, 1936.	3.8	28
223	The gut microbiota and psychiatric illness. <i>Journal of Psychiatry and Neuroscience</i> , 2017, 42, 75-77.	2.4	28
224	Establishing patient preferences for gastroenterology clinic reorganization using conjoint analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 429-433.	1.6	27
225	Cost-utility and cost-benefit analyses. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 527-534.	1.6	27
226	Mycophenolate mofetil in refractory inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1365-1369.	3.7	26
227	Bead study: a novel method to measure gastrointestinal transit in mice. <i>Neurogastroenterology and Motility</i> , 2014, 26, 1663-1668.	3.0	26
228	Managing dyspepsia without alarm signs in primary care: new national guidance for England and Wales. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1135-1143.	3.7	25
229	Clinical trial design in adult reflux disease: a methodological workshop. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 107-126.	3.7	25
230	A Second-Order Simulation Model of the Cost-Effectiveness of Managing Dyspepsia in the United States. <i>Medical Decision Making</i> , 2008, 28, 44-55.	2.4	24
231	Hip Fracture and Proton Pump Inhibitor Therapy: Balancing the Evidence for Benefit and Harm. <i>American Journal of Gastroenterology</i> , 2008, 103, 2428-2431.	0.4	23
232	The natural history of gastroesophageal reflux symptoms in the community and its effects on survival: a longitudinal 10-year follow-up study. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 323-331.	3.7	23
233	Sequential Therapy for Eradication of <i>Helicobacter pylori</i> : A New Guiding Light or a False Dawn?. <i>American Journal of Gastroenterology</i> , 2009, 104, 3081-3083.	0.4	21
234	Eradication of <i>Helicobacter pylori</i> for non-ulcer dyspepsia. <i>The Cochrane Library</i> , 2011, , CD002096.	2.8	21

#	ARTICLE	IF	CITATIONS
235	Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. <i>Cmaj</i> , 2013, 185, E156-E166.	2.0	21
236	Analysis of Genetic Association of Intestinal Permeability in Healthy First-degree Relatives of Patients with Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1796-1804.	1.9	21
237	The Influence of <i>Helicobacter pylori</i> Status on Circulating Levels of the Coagulation Factors Fibrinogen, von Willebrand Factor, Factor VII, and Factor VIII. <i>Helicobacter</i> , 1996, 1, 65-69.	3.5	20
238	Should We Test for <i>Helicobacter Pylori</i> before Treating Gastroesophageal Reflux Disease?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 425-427.	1.7	20
239	Acid-Suppressive Therapy With Esomeprazole for Relief of Unexplained Chest Pain in Primary Care: A Randomized, Double-Blind, Placebo-Controlled Trial. <i>American Journal of Gastroenterology</i> , 2013, 108, 56-64.	0.4	20
240	Stress ulcer prophylaxis in critically ill patients: review of the evidence. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 107-114.	0.4	20
241	Non-Erosive Reflux Disease " Defining the Entity and Delineating the Management. <i>Digestion</i> , 2008, 78, 1-5.	2.3	19
242	Pharmacological interventions for non-ulcer dyspepsia. <i>The Cochrane Library</i> , 2011, 2011, CD001960.	2.8	19
243	Invited Commentary: Clues to the Etiology of Inflammatory Bowel Disease" A Return to John Snow?. <i>American Journal of Epidemiology</i> , 2006, 164, 624-626.	3.4	18
244	Barrett's Esophagus and Obesity: The Missing Part of the Puzzle. <i>American Journal of Gastroenterology</i> , 2008, 103, 301-303.	0.4	18
245	Redundant Data in the Meta-analysis on <i>Helicobacter pylori</i> Eradication. <i>Annals of Internal Medicine</i> , 2009, 151, 513.	3.9	18
246	Dyspepsia. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 662-668.	2.3	18
247	No increase in prevalence of somatization in functional vs organic dyspepsia: a cross-sectional survey. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1024-1031.	3.0	18
248	Is there a rationale for eradication of <i>Helicobacter pylori</i> ? Cost-benefit: the case for. <i>British Medical Bulletin</i> , 1998, 54, 243-250.	6.9	17
249	Proton Pump Inhibitors and Clopidogrel " Hazardous Drug Interaction or Hazardous Interpretation of Data?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009, 23, 251-252.	1.7	17
250	Dyspepsia. <i>Current Opinion in Gastroenterology</i> , 2012, 28, 602-607.	2.3	17
251	Lost in Translation: The Gut Microbiota in Psychiatric Illness. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 460-463.	1.9	17
252	Prevalence and risk factors for lymph node metastasis after noncurative endoscopic resection for early gastric cancer: a systematic review and meta-analysis. <i>Journal of Gastroenterology</i> , 2020, 55, 742-753.	5.1	17

#	ARTICLE	IF	CITATIONS
253	Symptom-Based Diagnostic Criteria for Irritable Bowel Syndrome: the More Things Change, the More They Stay the Same. <i>Gastroenterology Clinics of North America</i> , 2011, 40, 87-103.	2.2	16
254	Randomized controlled trial comparing telephone and mail follow-up for recruitment of participants into a clinical trial of colorectal cancer screening. <i>Trials</i> , 2013, 14, 40.	1.6	16
255	Management of Pancreatic Cysts in an Evidence-Based World. <i>Gastroenterology</i> , 2015, 148, 692-695.	1.3	16
256	Lack of Utility of Symptoms and Signs at First Presentation as Predictors of Inflammatory Bowel Disease in Secondary Care. <i>American Journal of Gastroenterology</i> , 2015, 110, 716-724.	0.4	16
257	Pancreatic duct guidewire placement for biliary cannulation for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. <i>The Cochrane Library</i> , 2016, , CD010571.	2.8	16
258	Fecal transplantation. <i>Current Opinion in Gastroenterology</i> , 2016, 32, 282-286.	2.3	16
259	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, e35-e63.	0.3	16
260	Diarrhoea: interventions, consequences and epidemiology in the intensive care unit (DICE-ICU): a protocol for a prospective multicentre cohort study. <i>BMJ Open</i> , 2019, 9, e028237.	1.9	16
261	Interpreting Reported Risks Associated With Use of Proton Pump Inhibitors: Residual Confounding in a 10-Year Analysis of National Ambulatory Data. <i>Gastroenterology</i> , 2020, 158, 780-782.e3.	1.3	16
262	Pseudomonas and Endoscopy. <i>Endoscopy</i> , 1994, 26, 554-558.	1.8	15
263	Significance of Helicobacter Pylori Infection and Gastric Cancer: Implications for Screening. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1997, 7, 47-64.	1.4	15
264	Recent developments in gastroenterology. <i>BMJ: British Medical Journal</i> , 2002, 325, 1399-1402.	2.3	15
265	Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, e1-e9.	0.3	15
266	Helicobacter pylori and nonmalignant disease. <i>Helicobacter</i> , 2002, 7, 30-36.	3.5	13
267	Methods and Economic Considerations: Group 1 Report. <i>Endoscopy</i> , 2004, 36, 349-353.	1.8	13
268	Initial management strategies for dyspepsia. <i>The Cochrane Library</i> , 2009, , CD001961.	2.8	13
269	Proton Pump Inhibitors in the Elderly, Balancing Risk and Benefit: an Age-Old Problem. <i>Current Gastroenterology Reports</i> , 2019, 21, 65.	2.5	13
270	COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqu� From the Canadian Association of Gastroenterology. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 49-49.	0.3	13

#	ARTICLE	IF	CITATIONS
271	Does long term aspirin prevent cancer?. BMJ: British Medical Journal, 2010, 341, c7326-c7326.	2.3	13
272	Randomised study of efficacy of Omeprazole and clarithromycin with either amoxicillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients. Digestive and Liver Disease, 2001, 33, 131-134.	0.9	12
273	The association between Helicobacter pylori infection and adult height. European Journal of Epidemiology, 2005, 20, 455-465.	5.7	12
274	Dyspepsia. BMJ, The, 2013, 347, f5059-f5059.	6.0	12
275	Canadian Association of Gastroenterology Position Statement: Hip Fracture and Proton Pump Inhibitor Therapy – a 2013 Update. Canadian Journal of Gastroenterology & Hepatology, 2013, 27, 593-595.	1.7	12
276	American Gastroenterological Association Institute Technical Review on Initial Testing and Management of Acute Liver Disease. Gastroenterology, 2017, 152, 648-664.e5.	1.3	12
277	Clinical trial: knowledge of negative <i>Helicobacter pylori</i> status reduces subsequent dyspepsia-related resource use. Alimentary Pharmacology and Therapeutics, 2007, 26, 1267-1275.	3.7	11
278	Polymorphisms of 5-HTT LPR and GNP3 825C>T and Response to Antidepressant Treatment in Functional Dyspepsia: A Study from The Functional Dyspepsia Treatment Trial. American Journal of Gastroenterology, 2017, 112, 903-909.	0.4	11
279	Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care. Alimentary Pharmacology and Therapeutics, 2017, 45, 91-99.	3.7	11
280	A Comparison of the Prevalence of Anxiety and Depression Between Uncomplicated and Complex IBD Patient Groups. Gastroenterology Nursing, 2018, 41, 427-435.	0.4	11
281	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. BMC Medical Genetics, 2020, 21, 204.	2.1	11
282	Who Needs Gastroprotection in 2020?. Current Treatment Options in Gastroenterology, 2020, 18, 557-573.	0.8	11
283	Germline variation in the insulin-like growth factor pathway and risk of Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis, 2021, 42, 369-377.	2.8	11
284	Helicobacter pylori infection in subjects with acute ischaemic stroke. Digestive and Liver Disease, 2003, 35, 16-19.	0.9	10
285	Eradicating H pylori. BMJ: British Medical Journal, 2004, 328, 1388-1389.	2.3	10
286	Cost-effectiveness and long-term impact of Helicobacter pylori test and treat service in reducing open access endoscopy referrals. European Journal of Gastroenterology and Hepatology, 2004, 16, 981-986.	1.6	10
287	Hip Fracture and Proton Pump Inhibitor Therapy: Position Statement. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 855-856.	1.7	10
288	Managing dyspepsia. Current Gastroenterology Reports, 2009, 11, 288-294.	2.5	10

#	ARTICLE	IF	CITATIONS
289	Costâ€utility analysis of proton pump inhibitors and other gastroâ€protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal antiâ€inflammatory agents. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 1354-1364.	3.7	10
290	Derivation and validation of a diagnostic test for irritable bowel syndrome using latent class analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 824-832.	3.7	10
291	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohnâ€™s Disease: The Toronto Consensus. <i>Journal of the Canadian Association of Gastroenterology</i> , 2018, 1, 141-154.	0.3	10
292	Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study. <i>Gastroenterology</i> , 2021, 161, 1333-1335.e1.	1.3	10
293	What is the Prevalence of Clinically Significant Endoscopic Findings in Subjects With Dyspepsia? Updated Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1739-1749.e2.	4.4	10
294	Aspirin in the prevention of cancer. <i>Lancet, The</i> , 2011, 377, 1649-1650.	13.7	9
295	The impact of intensifying acid suppression on sleep disturbance related to gastroâ€oesophageal reflux disease in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 730-737.	3.7	9
296	Proton Pump Inhibitors and Dementia: Deciphering the Data. <i>American Journal of Gastroenterology</i> , 2017, 112, 1809-1811.	0.4	9
297	Association of Medical Microbiology and Infectious Disease Canada treatment practice guidelines for <i>Clostridium difficile</i> infection. <i>Jammi</i> , 2018, 3, 71-92.	0.5	9
298	The Efficacy of Probiotics in the Therapy of Irritable Bowel Syndrome (IBS). <i>American Journal of Gastroenterology</i> , 2008, 103, S481.	0.4	9
299	Counting the cost of proton pump inhibitors. <i>Gut</i> , 2001, 49, 462-463.	12.1	8
300	Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1805.	1.3	8
301	Does aspirin really reduce the risk of colon cancer?. <i>Lancet, The</i> , 2012, 379, 1586-1587.	13.7	8
302	Whom should we "test and treat" for <i>Helicobacter pylori</i> ?. <i>BMJ, The</i> , 2014, 348, g3320-g3320.	6.0	8
303	Diarrhea during critical illness: a multicenter cohort study. <i>Intensive Care Medicine</i> , 2022, 48, 570-579.	8.2	8
304	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 253-264.	3.7	8
305	POPULATION-BASED AND OPPORTUNISTIC SCREENING AND ERADICATION OF <i>HELICOBACTER PYLORI</i> . <i>International Journal of Technology Assessment in Health Care</i> , 1999, 15, 649-660.	0.5	7
306	Gambling with Gastroesophageal Reflux Disease: Should We Worry about the QALY?. <i>American Journal of Gastroenterology</i> , 2005, 100, 534-536.	0.4	7

#	ARTICLE	IF	CITATIONS
307	A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire. <i>Internal and Emergency Medicine</i> , 2010, 5, 501-506.	2.0	7
308	The American College of Gastroenterology Irritable Bowel Syndrome Monograph: Translating Systematic Review Data to Clinical Practice. <i>Gastroenterology</i> , 2010, 138, 789-791.	1.3	7
309	Assessing the Value of Symptom Relief for Patients with Gastroesophageal Reflux Disease Treatment: Willingness to Pay Using a Discrete Choice Experiment. <i>Value in Health</i> , 2013, 16, 588-598.	0.3	7
310	Proton pump inhibitors and gastric cancer: association is not causation. <i>Gut</i> , 2019, 68, 1529.2-1530.	12.1	7
311	Patient Engagement and Multidisciplinary Involvement Has an Impact on Clinical Guideline Development and Decisions: A Comparison of Two Irritable Bowel Syndrome Guidelines Using the Same Data. <i>Journal of the Canadian Association of Gastroenterology</i> , 2019, 2, 30-36.	0.3	7
312	How to advise patients on the risk of chronic proton pump inhibitor therapy. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 317-322.	2.3	7
313	Peppermint Oil in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2020, 159, 395-396.	1.3	7
314	Patients'™ Experiences and Challenges in Living with Inflammatory Bowel Disease: A Qualitative Approach. <i>Clinical and Experimental Gastroenterology</i> , 2021, Volume 14, 123-131.	2.3	7
315	Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. <i>The Cochrane Library</i> , 2022, 2022, CD009662.	2.8	7
316	Endoscopy and Gastric Ulcers. <i>Endoscopy</i> , 1995, 27, 689-693.	1.8	6
317	<i>Helicobacter pylori</i> and gastro-oesophageal reflux disease – Authors' reply. <i>Lancet</i> , The, 2006, 368, 986-987.	13.7	6
318	Who Pays the Piper?. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S97-S101.	2.2	6
319	Passing the Torch: The American Journal of Gastroenterology 2010. <i>American Journal of Gastroenterology</i> , 2010, 105, 4-7.	0.4	6
320	Management of reflux-related symptoms. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 387-400.	2.4	6
321	An index with improved diagnostic accuracy for the diagnosis of Crohn's disease derived from the Lennard-Jones criteria. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 601-611.	3.7	6
322	Finding the optimum treatment for <i>Helicobacter pylori</i> . <i>Digestive and Liver Disease</i> , 2000, 32, 116-118.	0.9	5
323	CON: Patients with GERD Should Be Screened Once at Least for Barrett's Esophagus-Medicine or Magic?. <i>American Journal of Gastroenterology</i> , 2004, 99, 2293-2295.	0.4	5
324	NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias. <i>Lancet Oncology</i> , The, 2006, 7, 7-8.	10.7	5

#	ARTICLE	IF	CITATIONS
325	CON: Evidence-Based Medicine-The Emperor's New Clothes?. American Journal of Gastroenterology, 2008, 103, 2967-2969.	0.4	5
326	Virtual colonoscopy, optical colonoscopy, or fecal occult blood testing for colorectal cancer screening: results of a pilot randomized controlled trial. Trials, 2015, 16, 296.	1.6	5
327	Is Blood Urea Concentration an Independent Predictor of Positive Endoscopic Findings in Presumed Upper Gastrointestinal Bleeding?. Digestive Diseases, 2020, 38, 77-84.	1.9	5
328	IMAGINE Network's Mind And Gut Interactions Cohort (MAGIC) Study: a protocol for a prospective observational multicentre cohort study in inflammatory bowel disease and irritable bowel syndrome. BMJ Open, 2020, 10, e041733.	1.9	5
329	Is it safe to use a proton pump inhibitor with clopidogrel?. Polish Archives of Internal Medicine, 2009, 119, 564-568.	0.4	5
330	Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. The Cochrane Library, 2022, 2022, CD005415.	2.8	5
331	<i>Helicobacter pylori</i> Eradication Therapy for Nonulcer Dyspepsia. Annals of Internal Medicine, 2002, 136, 555.	3.9	4
332	Validation of the short-form Leeds dyspepsia questionnaire (SF-LDQ) in a community setting. Gastroenterology, 2003, 124, A224.	1.3	4
333	A glossary of economic terms. European Journal of Gastroenterology and Hepatology, 2004, 16, 563-565.	1.6	4
334	The Promises and Perils of Nurse-Led Flexible Sigmoidoscopy Screening. Canadian Journal of Gastroenterology & Hepatology, 2007, 21, 280-282.	1.7	4
335	Economic Reflections on Proton Pump Inhibitor Therapy for Non-Erosive Reflux Disease. Digestion, 2008, 78, 61-69.	2.3	4
336	Treatment of chronic gastro-oesophageal reflux disease. BMJ: British Medical Journal, 2009, 339, b2481-b2481.	2.3	4
337	10-biomarker algorithm to identify irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 2009, 30, 95-96.	3.7	4
338	The gut microbiome: Potential innovations for the understanding and treatment of psychopathology.. Canadian Psychology, 2016, 57, 67-75.	2.1	4
339	Faecal microbiota transplantation for IBS: still a long way to go. The Lancet Gastroenterology and Hepatology, 2019, 4, 656-657.	8.1	4
340	Leaving No Stone Unturned in the Search for Adverse Events Associated With Use of Proton Pump Inhibitors. Clinical Gastroenterology and Hepatology, 2021, 19, 41-42.	4.4	4
341	Current Status of Chemoprevention in Barrett's Esophagus. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 117-130.	1.4	4
342	Reduction in Anxiety and Depression Scores Associated with Improvement in Quality of Life in Patients with Inflammatory Bowel Disease. Journal of the Canadian Association of Gastroenterology, 2022, 5, 12-17.	0.3	4

#	ARTICLE	IF	CITATIONS
343	Proton Pump Inhibitor Use: A Risk Factor for Inflammatory Bowel Disease or an Innocent Bystander?. <i>Gastroenterology</i> , 2021, 161, 1789-1791.	1.3	4
344	<i>Helicobacter pylori</i> : the research explosion. <i>Current Opinion in Infectious Diseases</i> , 1995, 8, 374-379.	3.1	3
345	<i>Helicobacter pylori</i> : a clinical update. <i>Journal of Applied Microbiology</i> , 2001, 90, 126S-133S.	3.1	3
346	Helping patients to help themselves: the future for management of ulcerative colitis?. <i>Gut</i> , 2002, 51, 309-310.	12.1	3
347	Bringing science to the art of diagnosis. <i>Gut</i> , 2004, 53, 627-628.	12.1	3
348	Measuring Gastroesophageal Reflux Symptoms: Musings from Marrakech. <i>American Journal of Gastroenterology</i> , 2005, 100, 19-20.	0.4	3
349	Colorectal Cancer Screening with Fecal Occult Blood Testing (FOBT): An International Perspective. <i>American Journal of Gastroenterology</i> , 2006, 101, 212-212.	0.4	3
350	Prokinetics for functional dyspepsia. <i>The Cochrane Library</i> , 2011, , .	2.8	3
351	Minimal differences in prevalence and spectrum of organic disease at upper gastrointestinal endoscopy between selected secondary care patients with symptoms of gastro-oesophageal reflux or dyspepsia. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 396-402.	1.5	3
352	Proton-pump inhibitors for the prevention of upper gastrointestinal bleeding in adults receiving antithrombotic therapy. <i>The Cochrane Library</i> , 2019, , .	2.8	3
353	Fecal Microbiota Transplantation for the Treatment of Ulcerative Colitis: A Qualitative Assessment of Patient Perceptions and Experiences. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, e120-e129.	0.3	3
354	Dyspepsia results may not apply in primary care. <i>BMJ: British Medical Journal</i> , 2003, 327, 811-a-811.	2.3	3
355	Colorectal cancer screening lacks evidence of benefit.. <i>Cleveland Clinic Journal of Medicine</i> , 2007, 74, 545-545.	1.3	3
356	Should we stepâ€™up or stepâ€™down in the treatment of newâ€™onset dyspepsia in primary care?. <i>Polish Archives of Internal Medicine</i> , 2009, 119, 391-396.	0.4	3
357	Do young dyspeptics require endoscopy any more?. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, S63.	1.6	2
358	A systematic review of pharmacological therapies in non-ulcer dyspepsia. <i>Gastroenterology</i> , 2000, 118, A440.	1.3	2
359	The cost-effectiveness of population H pylori screening and treatment to reduce mortality from gastric cancer and peptic ulcer complications: A markov model using randomized controlled trial data. <i>Gastroenterology</i> , 2000, 118, A678.	1.3	2
360	Diagnosis of <i>helicobacter pylori</i> infection in acute upper gastrointestinal haemorrhage; what is the best diagnostic test?. <i>Gastroenterology</i> , 2000, 118, A1245.	1.3	2

#	ARTICLE	IF	CITATIONS
361	Power of Selective Serotonin Reuptake Inhibitors in Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 313-314.	4.4	2
362	Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. <i>Gut</i> , 2014, 63, 703.1-703.	12.1	2
363	Review: Calprotectin testing differentiates inflammatory bowel disease from the irritable bowel syndrome. <i>Annals of Internal Medicine</i> , 2014, 160, JC13.	3.9	2
364	Anti-inflammatory Intervention in Depression. <i>JAMA Psychiatry</i> , 2015, 72, 512.	11.0	2
365	P-079 The Association Between Anxiety and Depression and Health Related Quality of Life in Patients with Inflammatory Bowel Disease (IBD). <i>Inflammatory Bowel Diseases</i> , 2016, 22, S34.	1.9	2
366	Antidepressants for Functional Dyspepsia: New Indications for Old Therapies?. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 393-394.	4.4	2
367	Reply. <i>Gastroenterology</i> , 2017, 152, 303-304.	1.3	2
368	Antigliadin Antibodies Predict the Symptomatic Response to Gluten-Free Diet and Improvement in Gastrointestinal Motility in IBS Patients. <i>Gastroenterology</i> , 2017, 152, S45.	1.3	2
369	Antacids, sucralfate and bismuth salts for functional dyspepsia. <i>The Cochrane Library</i> , 0, , .	2.8	2
370	Development of a Global Rating Scale for Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 4-16.	0.3	2
371	Controversies Around Measuring Drug Toxicity: US Food and Drug Administration and Gastrointestinal Perspectives. <i>Gastroenterology</i> , 2020, 158, 22-27.	1.3	2
372	Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. , 2021, , .		2
373	Utility of Diagnostic Tests for Celiac Disease in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, S463.	0.4	2
374	Efficacy of Antidepressants in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2008, 103, S476-S477.	0.4	2
375	Endoscopic screening and surveillance for Barrett's esophagus—clinical implications. <i>MedGenMed: Medscape General Medicine</i> , 2006, 8, 88.	0.2	2
376	<i>Helicobacter pylori</i> infection. <i>Clinical Evidence</i> , 2009, 2009, .	0.2	2
377	Update on Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , 2018, 14, 319-322.	0.1	2
378	A patient-led, peer-to-peer qualitative study on the psychosocial relationship between young adults with inflammatory bowel disease and food. <i>Health Expectations</i> , 2022, , .	2.6	2

#	ARTICLE	IF	CITATIONS
379	The Serum 13 C-Bicarbonate Assay: A Replacement for Urea Breath Tests? Vector Potential of Houseflies (Musca domestica) for Helicobacter pylori . Reflux Esophagitis in Duodenal Ulcer Patients. Helicobacter, 1998, 3, 64-67.	3.5	1
380	A systematic review and economic analysis of the cost-effectiveness of H pylori eradication therapy in non-ulcer dyspepsia (NUD). Gastroenterology, 2000, 118, A471.	1.3	1
381	A systematic review of Helicobacter pylori eradication therapy in duodenal and gastric ulcer healing and maintenance. Gastroenterology, 2003, 124, A359.	1.3	1
382	Gastroesophageal reflux is more prominent in western dyspeptics: A prospective comparison study of British and South East Asian patients with dyspepsia. Gastroenterology, 2003, 124, A168.	1.3	1
383	A systematic review and economic analysis of the cost-effectiveness of proton pump inhibitor therapy in non-ulcer dyspepsia. Gastroenterology, 2003, 124, A182.	1.3	1
384	Should triple therapy for Helicobacter pylori eradication be prescribed for 1 week or 2 weeks?. Nature Reviews Gastroenterology & Hepatology, 2007, 4, 596-597.	1.7	1
385	Detection of Intestinal Metaplasia in Barrett's Esophagus. American Journal of Gastroenterology, 2007, 102, 2353-2354.	0.4	1
386	Review: eradication therapy supplemented by probiotics increased eradication rates and reduced side effects in H pylori infection. Evidence-Based Medicine, 2007, 12, 84-84.	0.6	1
387	Mortality risks associated with Barrett's oesophagus: authors' reply. Alimentary Pharmacology and Therapeutics, 2008, 27, 853-854.	3.7	1
388	Response:. Gastrointestinal Endoscopy, 2008, 68, 810-811.	1.0	1
389	Testing for Celiac Disease in Patients With Symptoms of Irritable Bowel Syndrome—Reply. JAMA - Journal of the American Medical Association, 2009, 301, 1126.	7.4	1
390	Stoking the Flame: The American Journal of Gastroenterology 2013. American Journal of Gastroenterology, 2013, 108, 162-165.	0.4	1
391	Reply. Gastroenterology, 2015, 149, 826.	1.3	1
392	Sa1085 Telephone vs. Clinic Follow-Up in the Management of Patients With Inflammatory Bowel Disease: A Nurse Practitioner Led Study. Gastroenterology, 2016, 150, S235.	1.3	1
393	Optimal strategies for pancreatic cyst surveillance: we need better comparative data, not more case series. Gastrointestinal Endoscopy, 2017, 85, 685-686.	1.0	1
394	Gluten Free Diet Improves Upper GI Symptoms and Promotes Changes in Gastric Emptying in IBS Patients with Functional Dyspepsia. Gastroenterology, 2017, 152, S939.	1.3	1
395	Prokinetics for functional dyspepsia. The Cochrane Library, 0, , .	2.8	1
396	Signature Celebration of Gastroenterology , Colorectal Cancer. Gastroenterology, 2018, 154, 767-770.	1.3	1

#	ARTICLE	IF	CITATIONS
397	Response to Marlicz et al. American Journal of Gastroenterology, 2018, 113, 781.	0.4	1
398	Canadian Association of Gastroenterology Statement on the Putative Link Between Proton Pump Inhibitor Treatment and Gastric Cancer after Helicobacter pylori Eradication. Journal of the Canadian Association of Gastroenterology, 2018, 1, 155-158.	0.3	1
399	Editorial: the overlap between dyspepsia and gastroesophageal reflux is duodenal eosinophilia the missing link?. Alimentary Pharmacology and Therapeutics, 2019, 50, 454-455.	3.7	1
400	460 Effects of Proton-Pump Inhibitors in Patients Receiving Clopidogrel-Based Antithrombotic Therapy for Cardiovascular Prevention: A Systematic Review and Meta-Analysis of Randomized Trials. Gastroenterology, 2019, 156, S-97.	1.3	1
401	Letter: meta-analysis of prebiotics, probiotics, synbiotics and antibiotics in IBS. Authors' reply. Alimentary Pharmacology and Therapeutics, 2019, 49, 1254-1255.	3.7	1
402	Reply. Gastroenterology, 2020, 158, 1175-1176.	1.3	1
403	Psychological interventions for reducing anxiety in patients undergoing first-time colonoscopy. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	1
404	IMPROVING PATIENT PARTICIPATION IN LONGITUDINAL RESEARCH: AN INNOVATIVE PATIENT-LED PATIENT-ORIENTED QUALITATIVE RESEARCH PROJECT TO UNDERSTAND THE MOTIVATIONS AND BARRIERS TO GETTING AND STAYING INVOLVED IN THE IMAGINE SPOR STUDY. Inflammatory Bowel Diseases, 2021, 27, S50-S50.	1.9	1
405	Bran's deleterious effects: much ado about nothing. BMJ: British Medical Journal, 2009, 339, b3956-b3956.	2.3	1
406	Chemoprevention of esophageal cancer with esomeprazole and aspirin therapy: Efficacy and safety in the phase III randomized factorial ASPECT trial.. Journal of Clinical Oncology, 2018, 36, LBA4008-LBA4008.	1.6	1
407	Efficacy of 5HT4-Agonists in Non-Diarrhea Predominant Irritable Bowel Syndrome. American Journal of Gastroenterology, 2008, 103, S478.	0.4	1
408	eQTL set-based association analysis identifies novel susceptibility loci for Barrett's esophagus and esophageal adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 0, , .	2.5	1
409	OVER THE FENCE. Helicobacter, 1996, 1, 123-124.	3.5	0
410	Mouth-Watering Prospects for Helicobacter pylori Diagnosis?. Helicobacter, 1997, 2, 53-55.	3.5	0
411	Cost-effectiveness of strategies for managing dyspepsia in primary care: A discrete event simulation. Gastroenterology, 2000, 118, A468-A469.	1.3	0
412	How much are patients with dyspepsia willing to pay for endoscopy compared with an H pylori "test and treat" service?. Gastroenterology, 2000, 118, A462.	1.3	0
413	Establishing patient preferences for one-stop gastrointestinal clinics using conjoint analysis. Gastroenterology, 2000, 118, A722.	1.3	0
414	Managing dyspepsia in primary care: A systematic review. Gastroenterology, 2000, 118, A1249.	1.3	0

#	ARTICLE	IF	CITATIONS
415	Supine duodeno-gastro-oesophageal bile reflux measured with the Bilitec-2000 appears to protect against the presence of microscopic intestinal metaplasia at the cardia. <i>Gastroenterology</i> , 2000, 118, A26.	1.3	0
416	Test-and-eradicate scheme for <i>Helicobacter pylori</i> is as safe and efficient as prompt endoscopy. <i>Evidence-Based Healthcare and Public Health</i> , 2001, 5, 46.	0.0	0
417	How best to assess symptomatic outcomes of therapy in gastro-oesophageal reflux disease trials: A systematic review. <i>Gastroenterology</i> , 2003, 124, A72.	1.3	0
418	A systematic review of the efficacy of proton pump inhibitors (PPIs), H2 receptor antagonists (H2RAs) and prokinetics in maintenance therapy of esophagitis. <i>Gastroenterology</i> , 2003, 124, A108-A109.	1.3	0
419	Early diagnosis or prevention of gastric cancer with <i>H.pylori</i> – Test and treat? A discrete event simulation model. <i>Gastroenterology</i> , 2003, 124, A180-A181.	1.3	0
420	Screening for Stomach Cancer. , 0, , 172-187.		0
421	<i>Helicobacter pylori</i> test-and-eradicate strategy versus early endoscopy in patients with dyspepsia. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 70-71.	1.7	0
422	Distinguishing Organic and Functional Dyspepsia by History. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1352.	7.4	0
423	Response to Dr. Zappa and Colleagues. <i>American Journal of Gastroenterology</i> , 2006, 101, 2433-2434.	0.4	0
424	Endoscopic Ultrasound: A Meta-Analysis of Test Performance in Suspected Choledocholithiasis. <i>Gastrointestinal Endoscopy</i> , 2007, 65, AB360.	1.0	0
425	Response to Cappell. <i>American Journal of Gastroenterology</i> , 2010, 105, 1901-1902.	0.4	0
426	Response to Atreja et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 2046.	0.4	0
427	Response to Yang et al.. <i>American Journal of Gastroenterology</i> , 2011, 106, 2044.	0.4	0
428	Reply to Akobeng. <i>American Journal of Gastroenterology</i> , 2011, 106, 1857-1858.	0.4	0
429	Response to Doherty and Moss. <i>American Journal of Gastroenterology</i> , 2012, 107, 487-488.	0.4	0
430	Response to Kayhan et al.. <i>American Journal of Gastroenterology</i> , 2012, 107, 321-322.	0.4	0
431	High dose versus standard dose proton pump inhibitor for short term management of erosive reflux oesophagitis. <i>The Cochrane Library</i> , 0, , .	2.8	0
432	Proton pump inhibitor versus placebo in the short term management of gastro-esophageal reflux disease. <i>The Cochrane Library</i> , 0, , .	2.8	0

#	ARTICLE	IF	CITATIONS
433	Response to Nahon et al. and Marmo et al.. American Journal of Gastroenterology, 2013, 108, 1534-1535.	0.4	0
434	Crohn disease was not associated with increased risk for mortality. Annals of Internal Medicine, 2013, 159, JC12.	3.9	0
435	The authors reply. Critical Care Medicine, 2013, 41, e397-e398.	0.9	0
436	Reply to Kawakami et al.. Endoscopy, 2014, 46, 164-164.	1.8	0
437	The Light Shines on: American Journal of Gastroenterology 2015. American Journal of Gastroenterology, 2015, 110, 1638-1639.	0.4	0
438	Response to Atreja et al.. American Journal of Gastroenterology, 2015, 110, 346-347.	0.4	0
439	Mo1653 Improvement of Gastrointestinal Symptoms After Gluten-Free Diet in Patients With Irritable Bowel Syndrome Is Dependent on the Presence of Anti-Gliadin Antibodies. Gastroenterology, 2016, 150, S743-S744.	1.3	0
440	Sa1199 Protease Inhibitors for the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PEP): Cochrane Collaboration Meta-Analysis of Randomized Controlled Trials. Gastrointestinal Endoscopy, 2016, 83, AB252.	1.0	0
441	Response to Feuerstein J et al. "Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005-2013) for Barrett's Esophagus". doi:10.1007/s10620-016-4222-2. Digestive Diseases and Sciences, 2016, 61, 3369-3371.	2.3	0
442	P-231 Patient Experience Living with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, S79.	1.9	0
443	Editorial: latent class analysis to improve confidence in the diagnosis of IBS " authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1268-1269.	3.7	0
444	No Detrimental Effect of Oats on Symptoms, Histological Parameters, Serological Tests, or Quality of Life in Celiac Disease: A Systematic Review and Meta-Analysis. Gastroenterology, 2017, 152, S481.	1.3	0
445	Letter: NICE referral criteria for lower gastrointestinal alarm features " not ideal but not poor either. Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1176-1176.	3.7	0
446	Reply. Gastroenterology, 2018, 154, 764-765.	1.3	0
447	Imipramine for functional dyspepsia: a 60-year journey. The Lancet Gastroenterology and Hepatology, 2018, 3, 815-817.	8.1	0
448	Response to Letter by Moulton et al.. Inflammatory Bowel Diseases, 2019, 25, e99-e99.	1.9	0
449	PWE-076...Efficacy of Pharmacological Therapies in Patients with Irritable Bowel Syndrome with Diarrhoea: Network Meta-analysis. , 2019, , .		0
450	2885 Reducing Anxiety in Patients Undergoing First-Time Colonoscopy: A Pilot and Feasibility Study for a Randomized Controlled Trial. American Journal of Gastroenterology, 2019, 114, S1581-S1581.	0.4	0

#	ARTICLE	IF	CITATIONS
451	Reply. <i>Gastroenterology</i> , 2020, 158, 285-286.	1.3	0
452	Response to Comments on the CAG/CCC Position Statement on Biosimilars for Inflammatory Bowel Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , 2020, 3, 98-99.	0.3	0
453	Electrosurgical current for endoscopic biliary sphincterotomy (EBS) for the prevention of post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. <i>The Cochrane Library</i> , 2021, .	2.8	0
454	Triple Versus Quadruple Therapy as Primary Treatment for <i>Helicobacter pylori</i> Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, S397-S398.	0.4	0
455	Determining the Optimum Outcome for Trials Evaluating Symptom Improvement in Functional Gastrointestinal Disorders. <i>American Journal of Gastroenterology</i> , 2010, 105, S492-S493.	0.4	0
456	Quadruple Therapy Using a 3-in-1 Capsule of Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline with Omeprazole Compared to Triple Therapy for the Eradication of <i>Helicobacter pylori</i> : 2010 Presidential Poster. <i>American Journal of Gastroenterology</i> , 2010, 105, S44.	0.4	0
457	Gender Differences in Psychologic Parameters in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2011, 106, S504.	0.4	0
458	Electrosurgical Current for Endoscopic Biliary Sphincterotomy (EBS) for the Prevention of Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis (PEP): Cochrane Collaboration Meta-analysis of Randomized Controlled Trials. <i>American Journal of Gastroenterology</i> , 2012, 107, S719-S720.	0.4	0
459	Double Guidewire Technique for the Prevention of Post-ERCP Pancreatitis (PEP): Cochrane Collaboration Meta-analysis of RCTs. <i>American Journal of Gastroenterology</i> , 2013, 108, S60.	0.4	0
460	Effect of Antidepressants on Sleep in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2015, 110, S740-S741.	0.4	0
461	GORD in adults. <i>Clinical Evidence</i> , 2008, 2008, .	0.2	0
462	Declining Use of Corticosteroids for Crohn's Disease Has Implications for Study Recruitment: Results of a Pilot Randomized Controlled Trial. <i>Journal of the Canadian Association of Gastroenterology</i> , 2021, 4, 214-221.	0.3	0
463	Reliability and Validation of the Persian Version of JUICE Study Questionnaire. <i>Archives of Iranian Medicine</i> , 2022, 25, 1-5.	0.6	0
464	Gastro-oesophageal reflux disease. <i>Clinical Evidence</i> , 2003, , 496-512.	0.2	0
465	Gastro-oesophageal reflux disease. <i>Clinical Evidence</i> , 2005, , 567-81.	0.2	0